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Carrier Woman of Duchenne Muscular Dystrophy Mimicking 
Inflammatory Myositis
Carrier woman of Duchenne muscular dystrophy (DMD) can mimic the inflammatory 
myositis in presenting symptoms. Two diseases should be differentiated by the clinical 
history, muscle biopsy and genetic study. There are few reports in which both histochemical 
and genetic study showed the possible link of overlapping inflammatory pathophysiology 
with dystrophinopathy. We report a 40-yr-old woman who presented with subacute 
proximal muscle weakness and high serum level of creatine kinase. She had a history of 
Graves’ disease and fluctuation of serum liver aminotransferase without definite cause. 
MRI, EMG and NCV were compatible with proximal muscle myopathy. Muscle biopsy on 
vastus lateralis showed suspicious perifascicular atrophy and infiltration of mono-
macrophage lineage cells complicating the diagnosis. Dystrophin staining showed 
heterogeneous diverse findings from normal to interrupted mosaic pattern. Multiple 
ligation probe amplification and X chromosome inactivation test confirmed DMD gene 
deletion mutation in exon 44 and highly skewed X inactivation.
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CASE REPORT
Musculoskeletal Disorders
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a severe human X 
linked recessive disorder of muscle characterized by progres-
sive skeletal muscle wasting. The disease is caused by mutations 
in the dystrophin gene located on Xp21.2, which encodes a cy-
toskeletal protein in muscle. The incidence of DMD is about 1 
in 3,500 male births and approximately one-third of the DMD 
patients originate through new mutations, while the rest are in-
herited through carrier mothers or arise from germ line mosa-
icism (1). The disease generally affects male as it is X linked re-
cessive but female can manifest symptoms as heterozygous car-
riers of the disease (2). Late onset manifestation of carrier wom-
an could confuse the diagnosis for myopathy as it has often in-
discriminate clinical features of inflammatory myopathy. Fur-
thermore, overlapping inflammatory features on biopsy speci-
men could complicate the diagnosis. Recently we encountered 
a 40 yr old woman who presented with subacute proximal mus-
cle weakness and had more than ten times of the upper normal 
limit of serum creatinine kinase (CK) level mimicking inflamma-
tory myositis, but later she was revealed as a manifesting DMD 
carrier by gene analysis and X chromosome inactivation (XCI) 
study. Herein we describe the case and review the literatures. 
CASE DESCRIPTION
A 40-yr-old housewife woman was admitted on January 25, 2010 
to the rheumatism center because of 6-month history of increas-
ing proximal muscle weakness which was exacerbated rapidly 
one month earlier. 
  She had been an athlete during her high school period and 
had been in usual state of health until 3 yr earlier, when she de-
veloped weight loss and fatigue with diagnosis of Graves’ dis-
ease with thyrotoxicosis. At that time, her serum liver enzyme, 
alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST) level increased to 184 IU/mL, 94 IU/mL respectively 
without serologic evidence of viral hepatitis, which endocrinol-
ogist considered as a feature of thyrotoxicosis. After one and a 
half year long methimazole treatment, remission of hyperthy-
roidism was achieved. But her liver enzyme continued to fluc-
tuate within two times of upper normal range during the follow 
up. Eighteen month before admission, because she reported 
fatigue and weakness despite of euthyroid status, she was re-
ferred to gastroenterologist for the evaluation of persistent mild 
liver enzyme elevation. Her viral marker for hepatitis B and C 
were negative and ultrasonography showed innumerable small 
gall stone and small liver parenchymal calcification. She was Yoon J, et al.  •  Myopathy in Carrier Woman of Myositis
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instructed to be followed up regularly at gastroenterology de-
partment. One year before admission, weight loss and myalgia 
were developed with elevation of liver aminotransferase again 
up to 187 IU/mL of AST. She was undertaken ultrasonography 
guided liver biopsy which revealed minimal porto-periportal 
activity and minimal portal fibrosis. Anti-nuclear antibody (ANA) 
showed titer of 1:20 with speckled pattern. Anti-smooth muscle 
antibody and anti-LKM-1 antibody was negative. Prednisone 
and azathiopurine were prescribed by gastroenterologist for her 
long lasting elevation of liver enzyme under the impression of 
autoimmune hepatitis without definite cause. Six month before 
admission, recurrent myalgia, muscle weakness, and anorexia 
developed with fluctuation of liver aminotransferase serum lev-
els despite of treatment with azathiopurine and low dose pred-
nisone. Three month earlier, proximal muscle weakness became 
evident and she felt difficulty in climbing upstairs and worsen-
ing even thereafter. 
  On initial examination, she showed chronic ill-looking ap-
pearance and vital signs were within normal range. She could 
walk but complained of difficulty in climbing upstairs or raising 
arms. There was no specific skin lesion on her face or body. Dur-
ing the interview, we found that her two sons had been diag-
nosed as DMD in childhood and were bed-ridden status since 
long before. Her two brothers and parents were in usual health 
status, which suggests de novo mutation. Her serum CK level 
was 2,436 IU/mL, aldolase 11.9 IU/mL, LDH 312 IU/L. Serum 
TSH and free T4 were normal. Antinuclear antibody, anti-Jo-1 
antibody, and anti-PM-SCL antibody were all negative. Chest 
radiography showed normal finding. Fat suppression T2 weight-
ed MR image in the thigh level showed multiple atrophy in thigh 
muscles such as gluteus maximus, tensor fasciae latae, vastus 
lateralis and hamstring muscles. When contrast media admin-
istered, there was no gadolinium enhancement. Transthoracic 
2D echocardiography showed normal chamber size and good 
systolic function without evidence of pulmonary hypertension. 
Muscle biopsy of right vastus lateralis revealed myopathic change 
showing small group muscle atrophy with a few regenerating 
fibers and infiltration of inflammatory cell as well as suspicious 
area of perifascicular atrophy mimicking dermatomyositis. Ad-
ditional special staining showed positive staining for leukocyte 
common antigen (LCA), CD 68 but rarity for CD 4, CD 8, which 
meant the main inflammatory cells are macrophage-lineages. 
Dystrophin staining was not negative, but showed diverse stain-
ing pattern from normal to interrupted sarcolemmal activity in 
some area (Fig. 1). EMG-NCV study revealed short duration, 
small amplitude, increased insertional activity, positive sharp 
wave and fibrillation compatible with myopathy. Based on pro-
gressive features of myopathy with inflammatory evidence, high-
dose prednisone was tried at dosage of 1.0 mg/kg/day. After 2 
weeks of corticosteroid treatment, good response was observed 
as decreasing serum CK level to near normal and improving weak-
ness from grade 4 minus to grade 4 plus by Medical Research 
Council’s grading system. But initial steroid response was not 
lasted longer and her muscle weakness and fluctuating serum 
CK level was repeated on follow up despite continuation of oral 
prednisone. After 6 month of referral to our center, intravenous 
immunoglobulin and oral cyclosporine was tried but previous 
improvement of muscle enzyme and weakness were not ob-
served any more. 
  To identify the underlying genetic defect, we performed mo-
lecular genetic testing for the DMD gene. After we had obtained 
informed consent, blood sample was collected from the patient 
and genomic DNA was isolated. We performed multiple ligation 
probe amplification (MLPA) analysis using the test kits SALSA 
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Fig. 1. Muscle biopsy specimen of right vastus lateralis muscle. It shows variable sized muscle fiber, fatty infiltration, perimysial fibrosis, focal inflammatory infiltrates with the 
suspicious area of perifascicular atrophy in low power (A) and high power view (B). Perimysial atrophy mimicking dermatomyositis are also shown (C). Also regenerating fibers 
with inflammatory infiltration was shown (D, E). Dystrophin staining showed variable different staining pattern from normal to interruped mosaic pattern (F). Inflammatory cells 
are mainly macrophage-lineages on LCA (G), CD 68 (H) special staining with rarety of CD 4 and CD 8 positive cells (not shown).Yoon J, et al.  •  Myopathy in Carrier Woman of Myositis
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P034 DMD and P035 DMD from MRC-Holland (Amsterdam, 
Netherland) and revealed a heterozygote deletion mutation in-
volving exon 44 in this patient (3).
  The XCI pattern was determined by PCR analysis of a poly-
morphic CAG repeat in the HUMARA (4). Methylation of sites 
located close to this short tandem repeat correlates with XCI. 
After digestion with the methylation sensitive enzyme HpaII, a 
PCR product is obtained only from the inactive X chromosome. 
The PCR product was analyzed by GeneScan Software (Applied 
Biosystems, Foster City, CA, USA). XCI was calculated as the ra-
tio between the intensities of the PCR products of the two alleles 
with the smallest allele given first. The presence of skewed XCI 
was considered if the ratio was ≥ 35:65, and considered extreme-
ly skewed if the ratio was ≥ 20:80 (5). The heterozygous allele of 
the X chromosome in non-digested sample was shown with a 
CAG repeat polymorphism (Fig. 2). After DNA was digested with 
HpaII, the patient showed one distinct peak and one faint peak, 
indicating that these had a highly skewed XCI and the ratio was 
19:81.
 
DISCUSSION
Differential diagnosis for adulthood onset myopathy without 
definite infective or pharmacologic etiology in woman usually 
include inflammatory myositis such as polymyositis or derma-
tomyositis but, though rarely encountered in general population, 
late onset genetic disorder of muscular dystrophy also should 
be sought by means of special staining of muscle cells as well as 
genetic study as shown in this case. 
  There are few reports in which both histochemical and ge-
netic study showed the possible link of overlapping inflamma-
tory pathophysiology with dystrophinopathy in a normal karyo-
type woman. This case showed that late onset of myopathic 
symptoms in manifesting carrier of DMD with normal karyo-
type could complicate the diagnosis by overlapping inflamma-
tory features on muscle biopsy specimen if physician is unaware 
of the family history of DMD. In contrast to our case of normal 
karyotype, in Korea, there are two case reports of manifesting 
carrier of DMD in Turner syndrome (6, 7). One of them, 6 yr old 
girl, was confirmed by MLPA method but without histochemi-
cal finding and the other, 12 yr old girl, was confirmed by nega-
tive dystrophin staining on histochemical study but multiplex 
PCR was negative for DMD detection. Relatively early onset of 
manifestation in these two cases is related to their karyotype of 
Turner syndrome because of X-recessive nature of DMD. One 
retrospective study for DMD in Korea identified three carrier 
girls (8-10 yr of age) among 93 patients diagnosed with Duch-
enne or Becker muscular dystrophy from 1989 to 2008, but his-
tochemical findings or karyotype of carriers were not reported 
(8). 
  DMD, which is characterized by compromised sarcolemmal 
integrity from defective dystrophin-associated protein complex 
(DAPC), bound in skeletal myocyte membrane, cause progres-
sive myopathic weakness, gait disturbance and grossly elevated 
serum creatine kinase (CK) as a result of degenerating fibers. In 
male DMD patients, severe myopathic features develop in early 
and most of the patients are wheelchair bound by 10 to 15 yr of 
age (9). Women, as a heterozygous carrier of DMD gene in one 
of their two X chromosome, usually do not show severe myo-
pathic features because of possible compensation by normal X 
chromosome with inactivation of defected DMD gene in dis-
eased X chromosome, which occur randomly (10). But some-
times, this compensation could be reversed by nonrandom in-
activation of X chromosome enough to cause some degree of 
myopathic features. Non-random skewed X chromosome inac-
tivation is one of possible mechanism which inactivate prefer-
entially normal X chromosome (11). Other mechanisms of man-
ifesting carrier include X chromosome rearrangement involov-
ing DMD locus and complete or partial absence of X chromo-
some (Turner syndrome). 
  Unlikely to male DMD patients, manifesting carrier woman 
showed variable disease activity and could be undetected. Inci-
dence of manifestation carrier among DMD carrier women could 
be hardly assessed because of both variable severity of disease 
among carriers and different definitions for manifesting carrier. 
About 2.5%-10% of female carriers are classified as manifesting 
carriers for showing some degree of muscle weakness, and fre-
quently having enlarged calves (9, 12). One cohort study in Neth-
erlands reported that DMD carrier women showed symptom-
atic muscle weakness in 19%, myalgia in 5%, dilated cardiomy-
opathy in 8%, EKG abnormality in 47%, echocardiographic ab-
normality including cardiac chambers dilatation in 36%. Mean 
age at onset of symptoms was 33.6 yr while severe phenotypes 
Fig. 2. X chromosome inactivation (XCI) analysis in this patient. After digestion with 
HpaII, a PCR product is obtained from the inactive X chromosome. Highly skewed X 
chromosome inactivation is found with ratio of 19:81 compared to positive control. 
Patient
HpaII-
HpaII+
X inactivation 19:81 32:68
Positive 
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in girls were reported with rather young age (2, 13). Elevation of 
serum creatine kinase was common in as much as 50% of carri-
er. Though manifestation of DMD is not uncommon in carrier 
woman, the exact prevalence of carrier status among general 
population and the frequency of severe manifestation are not 
yet known in Korea.
  Our patient is also noticeable in the onset of symptoms in her 
late thirties and elevation of liver aminotransferase could not 
be regarded as a manifesting features initially, which leads to 
misdiagnosis of autoimmune hepatitis before referral to us. In 
one retrospective study in Korea, 37% of Duchenne/Becker dys-
trophy patients presented elevation of liver enzyme before the 
diagnosis in retrospective study in Korea (8).
  Muscle biopsy findings of manifesting carrier were investigat-
ed in previous reports in views of dystrophin staining (14). While 
the absence of dystrophin staining in muscle specimen is diag-
nostic in male DMD patients, specimen from manifesting car-
rier showed variable findings from normal to regional absence 
or mosaic pattern of sarcolemmal staining with anti-dystrophin 
which meant different presentation of abnormal dystrophin gene 
by myocyte within same patient (10). Mosaic pattern of dystro-
phin staining could be the result of compensated dystrophin 
production from multinucleated skeletal myocyte. Muscles of 
patients with DMD patients also exhibit inflammatory changes, 
which is same for manifesting carriers. Class I MHC antigens are 
known to be strongly expressed in skeletal myocytes of DMD 
patients and mononuclear cell infiltration with possible role of 
inflammatory cytokines to induce myocyte degeneration are 
observed as well as atrophy (15, 16). Infiltration by macrophages 
and T-cells as well as varying degree of degeneration could mim-
ic inflammatory myopathy. In the presenting case, finding of 
dominant macrophage infiltration with rare CD 4 and CD 8 T 
cells could be caused by prior corticosteroid therapy, which 
might obscure inflammatory T cell from biopsy specimen.
  Because of tremendous size (2.2 megabases), complexity (8 
promoters), and diversity of mutations within DMD gene, DNA 
testing for DMD presents a challenge for clinical laboratories. 
DMD gene contains 79 exons and its protein product, dystro-
phin, has 3,685 aminoacids with molecular weight of 427 kDa 
(17). While multiplex polymerase chain reaction (PCR) could 
detect 98% of mutations in affected male, multiplex PCR is not 
useful for detecting female carriers in whom deletions are mask-
ed by amplification of the normal X chromosome. In that rea-
son, we used multiple ligation probe amplification (MLPA) for 
deletion/duplication analysis of DMD gene and found deletion 
mutation in exon 44 area (3). Furthermore we performed non 
random X chromosome inactivation, skewed XCI, study to as-
certain the diagnosis of manifesting carrier and found highly 
skewed XCI ratio over 20:80, which correlated with severity of 
our patient.  
  Exact pathophysiologic mechanism of muscle degeneration 
is not yet determined in DMD and several possible mechanisms 
are mechanical membrane fragility, abnormal calcium homeo-
stasis with activating protease and mitochondrial overloading, 
abnormal gene regulation, and inflammation induced by im-
mune cells and cytokines (18). If it is the same for carrier wom-
an, in case of manifesting carrier of DMD with skewed X inacti-
vation, symptomatic myopathic features could be originated 
dependent to individual threshold for compensation of muscle 
degeneration. So the changing extent of imbalance between 
muscle degeneration and regeneration could result in both as-
ymptomatic carrier with high serum CK level in one patients 
and manifesting carrier with myopathic feature in another (18).
  Inflammatory myositis such as polymyositis or dermatomyo-
sitis is caused by immunological pathologic mechanism with-
out defect in cytoskeleton membrane protein but the diagnos-
tic criteria could be met in the case of manifesting carrier of 
DMD without careful consideration for muscular dystrophy 
even though there must be differentiation of these two disease 
entity (19). Most important point would be a different long-term 
treatment strategy in relation to immunosuppressive agent and 
prognosis. In pediatric DMD patients, studies have shown that 
prednisone improves the strength and function. It is hypothe-
sized that prednisone has a stabilizing effect on membranes and 
perhaps an anti-inflammatory effect could be beneficial for de-
lay in degeneration process. Though there is few report regard-
ing to corticosteroid use in manifesting carrier, our patient ini-
tially responded to corticosteroid therapy, which was not lasted 
longer. In pediatric patients, cyclosporine also was reported to 
improve clinical function in DMD children. Other emerging ther-
apies under evaluation include synthetic cyclosporine analogue 
as cyclophilin inhibitor, calpain inhibitor, oxandrolone as ana-
bolic steroid, pentoxifylline, and β-agonist such as albuterol. In 
regarding to overlapping inflammatory features of DMD, tumor 
necrosis factor-alpha (TNF-α) blocking agents are suggested 
based on the studies from mdx mouse, animal model for DMD, 
but not yet investigated in patients (20). 
  In conclusion, we report a 40-yr-old woman of myopathic 
feature mimicking inflammatory myositis as a manifesting car-
rier of DMD with highly skewed-XCI pattern by molecular ge-
netic analysis. Physicians should take caution in diagnosing in-
flammatory myositis based on clinical criteria because muscular 
dystrophy of adulthood could present with overlapping inflam-
matory features on biopsy. Careful pattern recognition for dys-
trophin staining with genetic study is necessary to make correct 
diagnosis. 
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